Search hospitals

>

North Dakota

>

Fargo

Essentia Health Cancer Center-South University Clinic

Claim this profile

Fargo, North Dakota 58103

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Cancer

150 reported clinical trials

2 medical researchers

Photo of Essentia Health Cancer Center-South University Clinic in FargoPhoto of Essentia Health Cancer Center-South University Clinic in Fargo

Summary

Essentia Health Cancer Center-South University Clinic is a medical facility located in Fargo, North Dakota. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Essentia Health Cancer Center-South University Clinic is involved with conducting 150 clinical trials across 299 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.

Area of expertise

1

Breast Cancer

Global Leader

Essentia Health Cancer Center-South University Clinic has run 36 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive
2

Lung Cancer

Global Leader

Essentia Health Cancer Center-South University Clinic has run 32 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Essentia Health Cancer Center-South University Clinic

Lung Cancer

Bladder Cancer

Breast Cancer

Esophageal cancer

Breast cancer

Pancreatic Cancer

Ovarian Cancer

Colorectal Cancer

Melanoma

Bladder Carcinoma

Image of trial facility.

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Recruiting

2 awards

Phase 3

28 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Essentia Health Cancer Center-South University Clinic?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security